August 24, 2016

The Lucrative Allergies Field

   August 24, 2016

The Lucrative Allergies Field

Mylan_EpiPen_Cost_And_Profit_Margin_Cost_of_2_EpiPens,_adjusted_EpiPen_Profit_margins_TMMChart.png

Share this chart

Editor’s Remarks:

Those suffering or acquainted with someone suffering from strong allergies have definitely heard of or own an EpiPen. The device essentially administers a shot of epinephrine which helps in case of anaphylaxis, buying more time before a person has to go to the emergency room. The autoinjector delivers epinephrine worth about $1, but the cost of the device has skyrocketed in recent years, with the price hiking 400%, persons signing petitions asking for help and some using home made solutions. Pharmaceuticals are developing a poor reputation for placing profits ahead of human interests with a number of high-profile investigations reported recently. The problem seems to arise from monopoly positions by pharma companies in certain areas of health and illness. However, if Mylan, the make of the EpiPen, who also gave its CEO a 671% salary bump over the last eight years, continue to force people into using less safe approaches, more federal investigations are likely.

Get articles like this straight to your inbox each morning with our Breakfast Briefing. Sign up by clicking here!

Log in with your details

or    

Forgot your details?

Create Account

Send this to a friend